Site-specific pegylation of a lysine-deficient TNF-α with full bioactivity

Nature Biotechnology

Volumn 21, Issue 5, 2003, Pages 546-552

  Yamamoto, Yoko ^a   Tsutsumi, Yasuo ^a   Yoshioka, Yasuo ^a   Nishibata, Toshihide ^a   Kobayashi, Kyoko ^a   Okamoto, Takayuki ^a   Mukai, Yohei ^a   Shimizu, Tomoe ^c   Nakagawa, Shinsaku ^a   Nagata, Satoshi ^b   Mayumi, Tadanori ^a  

^a OSAKA UNIVERSITY   (Japan)

^b Division of Clinical Sciences   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ANTIBODIES; POLYETHYLENE GLYCOLS; TUMORS;

ACTIVE SITES;

PROTEINS;

PEGINTERFERON ALPHA2B; PEGYLATED TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN MODIFICATION; PROTEIN STABILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BALB 3T3 CELLS; BINDING SITES; FEMALE; FIBROSARCOMA; HUMANS; LYSINE; MACROMOLECULAR SUBSTANCES; MICE; MUTAGENESIS, SITE-DIRECTED; PEPTIDE LIBRARY; POLYETHYLENE GLYCOLS; PROTEIN BINDING; PROTEIN ENGINEERING; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 12444305299     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt812     Document Type: Article

References (34)

1. Skillings, J. et al. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Immunother. 11, 67-70 (1992).
2. Price, T.H. et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95, 3302-3309 (2000).
3. Schmidinger, M. et al. Sequential administration of interferon-γ, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial. J. Immunother. 24, 257-262 (2001).
4. Kimura, K. et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother. Pharmacol. 20, 223-229 (1987).
5. Bory, C. et al. Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool. Adv. Exp. Med. Biol. 309A, 173-176 (1991).
6. Keating, M.J. et al. L-asparaginase and PEG asparaginase-past, present, and future. Leuk. Lymphoma 10 (Suppl.), 153-157 (1993).
7. Jen, J.F. et al. Population pharmacokinetic analysis of pegylated interferon α2b and interferon α2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther. 69, 407-421 (2001).
8. Poynard, T. et al. Impact of pegylated interferon α2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-1313 (2002).
9. Tsutsumi, Y. et al. Molecular design of hybrid tumour necrosis factor-α with polyethylene glycol increases its anti-tumour potency. Br. J. Cancer 71, 963-968 (1995).
10. Kaneda, Y. et al. Antitumor activity of tumor necrosis factor-α conjugated with divinyl ether and maleic anhydride copolymer on solid tumors in mice. Cancer Res. 58, 290-295 (1998).
11. Kamada, H. et al. Antitumor activity of tumor necrosis factor-α conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res. 60, 6416-6420 (2000).
12. Tsutsumi, Y. et al. PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb. Haemost. 77, 168-173 (1997).
13. Tsunoda, S. et al. Molecular design of polyvinylpyrrolidone-conjugated interleukin-6 for enhancement of in vivo thrombopoietic activity in mice. J. Control. Release 68, 335-341 (2000).
14. Tsutsumi, Y. et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97, 8548-8553 (2000).
15. Monkarsh, S.P. et al. Positional isomers of monopegylated interferon α2a: isolation, characterization, and biological activity. Anal. Biochem. 247, 434-440 (1997).
16. Bailon, P. et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α2a for the treatment of hepatitis C. Bioconjug. Chem. 12, 195-202 (2001).
17. Grace, M. et al. Structural and biologic characterization of pegylated recombinant IFN-α2b. J. Interferon Cytokine Res. 21, 1103-1115 (2001).
18. He, X.H. et al. Site-directed polyethylene glycol modification of trichosanthin: effects on its biological activities, pharmacokinetics, and antigenicity. Life Sci. 64, 1163-1175 (1999).
19. Kuan, C.T. et al. Pseudomonas exotoxin A mutants. Replacement of surface-exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J. Biol. Chem. 269, 7610-7616 (1994).
20. Carswell, E.A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666-3670 (1975).
21. Skillings, J. et al. A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. J. Immunother. 1, 67-70 (1992).
22. Sella, A. et al. Phase I study of tumor necrosis factor plus actinomycin D in patients with androgen-independent prostate cancer. Cancer Biother. 10, 225-235 (1995).
23. Jones, E.Y., Stuart, D.I. & Walker, N.P. Structure of tumour necrosis factor. Nature 338, 225-228 (1989).
24. Yamagishi, J. et al. Mutational analysis of structure-activity relationships in human tumor necrosis factor-α. Protein Eng. 3, 713-719 (1990).
25. Van Ostade, X. et al. Localization of the active site of human tumour necrosis factor (hTNF) by mutational analysis. EMBO J. 10, 827-836 (1991).
26. Smith, G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315-1317 (1985).
27. Parmley, S.F. et al. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73, 305-318 (1988).
28. Pasqualini, R. et al. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366 (1996).
29. Tsutsumi, Y. et al. Molecular design of hybrid tumor necrosis factor-α III: polyethylene glycol-modified tumor necrosis factor-α has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. J. Pharmacol. Exp. Ther. 278, 1006-1011 (1996).
30. Okada, N. et al. Elective enhancement by tumor necrosis factor-α of vascular permeability of new blood vessels induced with agarose hydrogel-entrapped Meth-A fibrosarcoma cells. Jpn. J. Cancer Res. 87, 831-836 (1996).
31. Chowdhury, S.P. et al. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17, 568-572 (1999).
32. Kurfurst, M.M. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200, 244-248 (1992).
33. National Institutes of Health. Principles of Laboratory Animal Care. NIH Publication 85-23, rev. (National Institutes of Health, Baltimore, MD, 1985).
34. Haranaka, K. et al. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int. J. Cancer 34, 263-267 (1984).